| Ferring B.V. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110230559 | Tranexamic Acid Formulations - Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith. | 09-22-2011 |
| 20110195900 | PEPTIDIC PTH RECEPTOR AGONISTS - Novel peptidic pth receptor agonists and methods of using the same are provided. | 08-11-2011 |
| 20110044905 | OXYTOCIN ANALOGUES - The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia compromised lactation conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 02-24-2011 |
| 20100261796 | Use of Novel Compounds for IBD Treatment - The present invention relates to use of novel compounds for the manufacture of a medicament for treatment of inflammatory bowel disease (IBD) as well as to a method for treatment of IBD, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 10-14-2010 |
| 20090275522 | Novel Compounds - The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 11-05-2009 |
| 20090054309 | Peptidic vasopressin receptor agonists - The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 02-26-2009 |
| 20090029965 | Vasopressin V1a Antagonists - The present invention concerns compounds inter alia according to general formula 1 | 01-29-2009 |
